EGFR and EGFRvIII coopt host defense pathways promoting progression in glioblastoma

作者：Zhenyi An, Qi-Wen Fan, Linyu Wang, Hiroyuki Yoda, Megumi J. Barata, David Jimenez‐Morales, Joanna J. Phillips, Danielle L. Swaney, Erica Stevenson, Ethan Lee, Nevan J. Krogan, William A. Weiss · 发表于：Neuro-Oncology · 年份：2024 · DOI：10.1093/neuonc/noae182 · 被引用次数：11 · 研究领域：Glioma Diagnosis and Treatment、Wnt/β-catenin signaling in development and cancer、Cell Adhesion Molecules Research

BACKGROUND: Co-amplification of the epidermal growth factor receptor (EGFR) and EGFRvIII, a tumor-specific truncation mutant of EGFR, represent hallmark genetic lesions in glioblastoma. METHODS: We used phospho-proteomics, RNA-sequencing, TCGA data, glioblastoma cell culture, and mouse models to study the signal transduction mediated by EGFR and EGFRvIII. RESULTS: We report that EGFR and EGFRvIII stimulate the innate immune defense receptor Toll-like Receptor 2 (TLR2); and that knockout of TLR2 dramatically improved survival in orthotopic glioblastoma xenografts. EGFR and EGFRvIII activated TLR2 in a ligand-independent manner, promoting tumor growth and immune evasion. We show that EGFR and EGFRvIII cooperate to activate the Rho-associated protein kinase ROCK2, which modulated malignant progression both by activating TLR2 and WNT signaling, and through remodeling the tumor microenvironment. CONCLUSIONS: Together, our findings show that EGFR and EGFRvIII cooperate to drive tumor progression through ROCK2 and downstream WNT-β-catenin/TLR2 signaling pathways.